Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DNM2 | P50570 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14869373 | 1.00 | SLC29A1 (0.50) | SLC29A1KCNH3KMT2ACA1CA2 | |
| SCHEMBL9913747 | 0.94 | CYP1A2 (0.50) | SLC29A1KCNH3KMT2ACA1CA2 | |
| SCHEMBL14869524 | 0.93 | KCNH3 (0.56) | SLC29A1KCNH3KMT2ACA1CA2 | |
| SCHEMBL14869427 | 0.92 | SLC29A1 (0.45) | SLC29A1KCNH3KMT2ACA1CA2 | |
| SCHEMBL2784426 | 0.91 | SLC29A1 (0.57) | SLC29A1KCNH3KMT2ACA1CA2 | |
| SCHEMBL13784076 | 0.90 | KMT2A (0.63) | SLC29A1KCNH3KMT2ACA1CA2 | |
| SCHEMBL14869403 | 0.90 | TLR8 (0.49) | SLC29A1KMT2ACA1CA2CA9 | |
| SCHEMBL21587503 | 0.88 | SLC29A1 (0.55) | SLC29A1KCNH3KMT2ACA1CA2 | |
| SCHEMBL13752164 | 0.88 | CA1 (0.43) | SLC29A1KCNH3KMT2ACA1CA2 | |
| SCHEMBL15720612 | 0.87 | KCNH3 (0.41) | SLC29A1KCNH3KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022081046-A1 | CHEMICAL COMPOUND COMPRISING A TRIAZINE GROUP AND METHOD FOR PRODUCING SAME | КУПРЮШКИН, Максим Сергеевич | 2022-04-21 | — | — | WO | disclosed |
| US-8198387-B2 | Proton-conducting compound and proton-conducting polymer | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100063249-A1 | PROTON-CONDUCTING COMPOUND AND PROTON-CONDUCTING POLYMER | NIPPON STREEL CHEMICAL CO., LTD (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063249-A1 | PROTON-CONDUCTING COMPOUND AND PROTON-CONDUCTING POLYMER | HRH3, H1-3, H1-4 | SLC29A1 535/4885KCNH3 49/4885KMT2A 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.